Pharmaceutical company, Avanos, declares transfer of its Hyaluronic Acid product line to medical distributor, Channel-Markers Medical.
Avanos Medical, a leading medical technology company based in Alpharetta, Georgia, has divested its Hyaluronic Acid (HA) product line to Channel-Markers Medical, a private medical device company specializing in joint health, regenerative therapies, and minimally invasive pain management solutions. This transaction, announced on July 31, 2025, involves the transfer of the injectable HA products TriVisc® and GenVisc® 850, which are used to treat osteoarthritis (OA) pain in the knee.
The divestiture aligns with Avanos' strategic transformation aimed at focusing on its core segments: Pain Management & Recovery, and Specialty Nutrition Systems. Avanos' CEO, Dave Pacitti, stated that this move will enable the company to better invest in areas with the greatest potential for innovation and growth, enhancing long-term value for patients, customers, and shareholders.
For Channel-Markers Medical, the acquisition supports its strategic goal to expand its presence in musculoskeletal health and injectable pain therapies. David Toledo, one of CMM's managing partners, stated that the acquisition aligns with their mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life.
The ownership transfer was effective immediately at the announcement, with Avanos providing transition support through the end of 2025 to maintain service continuity. This support ensures uninterrupted service and support for customers, partners, and patients.
In summary, this divestiture represents a strategic step for Avanos to concentrate on its prioritized business areas while allowing Channel-Markers Medical to broaden its musculoskeletal and pain management product portfolio. Avanos Medical remains focused on delivering clinically superior medical device solutions, while Channel-Markers Medical serves healthcare providers and patients across Orthopaedic, Sports Medicine, and Pain Management specialties.
For more information about Avanos Medical, visit www.avanos.com and follow them on X (@AvanosMedical), LinkedIn, and Facebook. To learn more about Channel-Markers Medical, visit www.channel-markers.com.
[1] Avanos Medical, Inc. Press Release. (2025, July 31). Avanos Medical Divests Hyaluronic Acid Product Line to Channel-Markers Medical, LLC. Business Wire. [2] Avanos Medical, Inc. Form 8-K. (2025, July 31). U.S. Securities and Exchange Commission. [3] Channel-Markers Medical, LLC Press Release. (2025, July 31). Channel-Markers Medical Acquires Avanos Medical's Hyaluronic Acid Product Line. Business Wire.
- The transfer of Avanos Medical's Hyaluronic Acid product line, which includes TriVisc® and GenVisc® 850, offers Channel-Markers Medical a chance to delve deeper into the field of injectable pain therapies, specifically those related to musculoskeletal health.
- This strategic move allows Avanos Medical to divert its resources towards its core segments, such as Pain Management & Recovery, and Specialty Nutrition Systems, with the hopes of fostering innovation and growth that will create long-term value for all stakeholders.
- It is expected that the ownership change will not impede the continuity of service and support for customers, partners, and patients, since Avanos Medical will continue to offer transition support until the end of 2025.
- Fitness enthusiasts and patients seeking health-and-wellness might find CBD's potential benefits in managing chronic diseases and ailments, just as they may turn to science-backed medical-condition treatments like the recently acquired injectable pain therapies from Avanos Medical.
